What is Amneal Pharmaceuticals, Inc.'s total revenue?

Amneal Pharmaceuticals, Inc. (AMRX) reported total revenue of $722.52M in Q1 2026.

How has Amneal Pharmaceuticals, Inc.'s total revenue changed year-over-year?

Amneal Pharmaceuticals, Inc.'s total revenue increased by 3.9% year-over-year, from $695.42M to $722.52M.

What is the long-term trend for Amneal Pharmaceuticals, Inc.'s total revenue?

Over 4 years (2021 to 2025), Amneal Pharmaceuticals, Inc.'s total revenue has grown at a 9.6% compound annual growth rate (CAGR), from $2.09B to $3.02B.

What does total revenue mean?

The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.

Amneal Pharmaceuticals, Inc. AMRX Total Revenue

Total Revenue at other companies

PfizerPFE

$14.45B+5.4%

Cardinal HealthCAH

$60.94B+11.0%

McKessonMCK

$96.3B+6.0%

CencoraCOR

$78.36B+3.8%

Jazz PharmaceuticalsJAZZ

$1.07B+19.1%

AbbVieABBV

$15B+12.4%

Segments

By product

See full

Subtotal dosage forms$417.92M+1.1%

Oral solid$171.1M-4.4%

Subtotal therapeutic classes$133.27M+23.1%

Distribution$89.15M-15.0%

Central nervous system$83.38M+23.3%

Transdermal$73.96M+71.8%

By segment

See full

Affordable Medicines$436.65M-0.6%

AvKARE$166.02M-3.7%

Specialty$133.27M+23.1%

Other financials

Income statement

See full

Gross profit$320.1M+25.1%

Operating income$141.8M+41.3%

Net income$62.3M+411%

EPS (diluted)$0.19+375%

Balance sheet

See full

Cash & equivalents$197.7M+234%

Total debt$2.6B+17.7%

Total equity-$45.4M+65.5%

Total assets$3.5B+5.2%

Cash flow

See full

Operating cash flow-$26.7M-461%

CapEx$8.2M-37.9%

Free cash flow-$34.9M-507%

Valuation

See full

Market cap$5.17B+51.0%

Enterprise value$7.55B+33.4%

P/E42.4×—

P/S1.7×+0.5×

Profitability

See full

Gross margin38.7%+2.0pp

Operating margin14.3%+1.6pp

Net margin4%+3.6pp

FCF margin7.9%-1.0pp

Returns & leverage

See full

Return on equity-52.8%-12.7pp

Debt / equity127.9×+119×

Current ratio2.5×+1.1×

Where this comes from

Reported directly by Amneal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amneal Pharmaceuticals, Inc.'s total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Amneal Pharmaceuticals, Inc.'s total revenue?: Amneal Pharmaceuticals, Inc. (AMRX) reported total revenue of $722.52M in Q1 2026.
How has Amneal Pharmaceuticals, Inc.'s total revenue changed year-over-year?: Amneal Pharmaceuticals, Inc.'s total revenue increased by 3.9% year-over-year, from $695.42M to $722.52M.
What is the long-term trend for Amneal Pharmaceuticals, Inc.'s total revenue?: Over 4 years (2021 to 2025), Amneal Pharmaceuticals, Inc.'s total revenue has grown at a 9.6% compound annual growth rate (CAGR), from $2.09B to $3.02B.
What does total revenue mean?: The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.